Evidence map›Paper›PMID 39537538›Full record

ReviewTrends in biochemical sciences2024

Eph receptor signaling complexes in the plasma membrane.

Elena B Pasquale

Abstract readReview
In one paragraph

Review in Trends in biochemical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Modulating pseudokinase conformation from the ATP-binding site.Structure (London, England : 1993) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Elena B PasqualeCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. Electronic address: elenap@sbpdiscovery.org.

Funding

Ligand functional selectivity in EphA2 receptor signalingR01GM131374 · NIGMS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Kalina Hristova, ELENA B PASQUALE · 2019 to 2026
$3.8M
Discovery of Selective Inhibitors for the EphA4 KinaseR01AG062617 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PASQUALE, ELENA B, SERGIENKO, EDUARD A. · 2020 to 2023
$3.0M
EPHA2 Receptor Signaling in Breast Cancer MechanotransductionR01CA262794 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE, Jing Yang · 2022 to 2026
$2.9M
NCI NIH HHS R01 CA262794NIA NIH HHS R01 AG062617NIGMS NIH HHS R01 GM131374
6 · The paper itself

Abstract

Eph receptor tyrosine kinases, together with their cell surface-anchored ephrin ligands, constitute an important cell-cell communication system that regulates physiological and pathological processes in most cell types. This review focuses on the multiple mechanisms by which Eph receptors initiate signaling via the formation of protein complexes in the plasma membrane. Upon ephrin binding, Eph receptors assemble into oligomers that can further aggregate into large complexes. Eph receptors also mediate ephrin-independent signaling through interplay with intracellular kinases or other cell-surface receptors. The distinct characteristics of Eph receptor family members, as well as their conserved domain structure, provide a framework for understanding their functional differences and redundancies. Possible areas of interest for future investigations of Eph receptor signaling complexes are also highlighted.

Indexed as

Cell MembraneReceptors, Eph FamilySignal TransductionAnimalsEphrinsHumansEphrinsReceptors, Eph FamilyEph receptorephrinphosphorylationreceptor tyrosine kinasesignaling platform

Identifiers

PMID39537538
PMCPMC11967910

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.